| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 27 | 2025 | 974 | 5.150 |
Why?
|
| Mental Disorders | 27 | 2024 | 463 | 4.730 |
Why?
|
| Smoking Cessation | 11 | 2025 | 272 | 4.160 |
Why?
|
| Gambling | 5 | 2021 | 168 | 2.170 |
Why?
|
| Antiretroviral Therapy, Highly Active | 9 | 2017 | 74 | 2.090 |
Why?
|
| Stress Disorders, Post-Traumatic | 6 | 2018 | 125 | 1.820 |
Why?
|
| Behavior Therapy | 5 | 2025 | 95 | 1.800 |
Why?
|
| Hepatitis C | 7 | 2022 | 184 | 1.630 |
Why?
|
| Depressive Disorder, Major | 6 | 2024 | 174 | 1.390 |
Why?
|
| Schizophrenia | 9 | 2016 | 532 | 1.360 |
Why?
|
| Methadone | 3 | 2017 | 50 | 1.350 |
Why?
|
| Depression | 8 | 2017 | 560 | 1.310 |
Why?
|
| Substance-Related Disorders | 8 | 2018 | 451 | 1.300 |
Why?
|
| Smoking | 6 | 2016 | 649 | 1.090 |
Why?
|
| Medication Adherence | 5 | 2020 | 122 | 1.060 |
Why?
|
| Opioid-Related Disorders | 4 | 2018 | 232 | 1.030 |
Why?
|
| Antipsychotic Agents | 6 | 2016 | 151 | 1.010 |
Why?
|
| Mental Health Services | 7 | 2024 | 78 | 1.000 |
Why?
|
| Behavior, Addictive | 2 | 2018 | 137 | 0.930 |
Why?
|
| Comorbidity | 16 | 2018 | 1011 | 0.920 |
Why?
|
| Middle Aged | 46 | 2025 | 28206 | 0.890 |
Why?
|
| Veterans | 7 | 2019 | 100 | 0.880 |
Why?
|
| Humans | 84 | 2025 | 95798 | 0.850 |
Why?
|
| Cigarette Smoking | 1 | 2025 | 48 | 0.840 |
Why?
|
| Antidepressive Agents | 5 | 2024 | 113 | 0.830 |
Why?
|
| Adult | 46 | 2025 | 28578 | 0.820 |
Why?
|
| Male | 57 | 2025 | 45685 | 0.800 |
Why?
|
| Depressive Disorder | 5 | 2017 | 226 | 0.800 |
Why?
|
| Nicotine | 1 | 2025 | 210 | 0.780 |
Why?
|
| Cross-Sectional Studies | 16 | 2023 | 1878 | 0.770 |
Why?
|
| Internet | 3 | 2017 | 340 | 0.760 |
Why?
|
| Female | 55 | 2025 | 49868 | 0.750 |
Why?
|
| Opiate Substitution Treatment | 3 | 2018 | 47 | 0.740 |
Why?
|
| Telephone | 2 | 2013 | 36 | 0.740 |
Why?
|
| Psychotropic Drugs | 4 | 2012 | 82 | 0.700 |
Why?
|
| Counseling | 5 | 2025 | 174 | 0.680 |
Why?
|
| Hospitalization | 6 | 2015 | 943 | 0.660 |
Why?
|
| Mass Screening | 6 | 2018 | 710 | 0.620 |
Why?
|
| Telemedicine | 2 | 2020 | 229 | 0.620 |
Why?
|
| Urban Population | 7 | 2025 | 240 | 0.610 |
Why?
|
| Psychiatry | 2 | 2015 | 90 | 0.610 |
Why?
|
| Smartphone | 2 | 2017 | 54 | 0.610 |
Why?
|
| Referral and Consultation | 4 | 2021 | 386 | 0.600 |
Why?
|
| Psychotherapy | 2 | 2011 | 73 | 0.600 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2014 | 296 | 0.570 |
Why?
|
| United States | 20 | 2025 | 7764 | 0.550 |
Why?
|
| Parkinson Disease | 2 | 2022 | 178 | 0.550 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 66 | 0.540 |
Why?
|
| Psychotic Disorders | 3 | 2016 | 231 | 0.530 |
Why?
|
| Patient Compliance | 5 | 2015 | 239 | 0.520 |
Why?
|
| Reminder Systems | 1 | 2017 | 18 | 0.510 |
Why?
|
| Anticonvulsants | 1 | 2018 | 133 | 0.510 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 180 | 0.500 |
Why?
|
| Students, Medical | 1 | 2022 | 455 | 0.500 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 787 | 0.490 |
Why?
|
| Smoking Prevention | 1 | 2016 | 46 | 0.490 |
Why?
|
| Prazosin | 1 | 2016 | 9 | 0.480 |
Why?
|
| Dreams | 1 | 2016 | 5 | 0.480 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 8 | 0.480 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 84 | 0.460 |
Why?
|
| Prevalence | 6 | 2023 | 1349 | 0.460 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2015 | 15 | 0.460 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2007 | 80 | 0.460 |
Why?
|
| Tobacco Use | 2 | 2025 | 31 | 0.450 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2015 | 25 | 0.450 |
Why?
|
| Adaptation, Psychological | 2 | 2018 | 174 | 0.450 |
Why?
|
| Delirium | 2 | 2013 | 79 | 0.450 |
Why?
|
| Impulsive Behavior | 1 | 2018 | 290 | 0.440 |
Why?
|
| Ketamine | 1 | 2015 | 27 | 0.440 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2015 | 82 | 0.440 |
Why?
|
| Religion | 1 | 2015 | 89 | 0.430 |
Why?
|
| Varenicline | 2 | 2025 | 16 | 0.430 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 128 | 0.430 |
Why?
|
| Teaching | 1 | 2015 | 154 | 0.420 |
Why?
|
| Pilot Projects | 5 | 2021 | 936 | 0.420 |
Why?
|
| Buprenorphine | 2 | 2018 | 51 | 0.420 |
Why?
|
| Feasibility Studies | 4 | 2021 | 816 | 0.410 |
Why?
|
| Bipolar Disorder | 2 | 2015 | 405 | 0.410 |
Why?
|
| Community Mental Health Services | 2 | 2013 | 21 | 0.400 |
Why?
|
| Evidence-Based Practice | 1 | 2014 | 51 | 0.400 |
Why?
|
| Mianserin | 1 | 2013 | 4 | 0.400 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2024 | 40 | 0.390 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2013 | 21 | 0.390 |
Why?
|
| Poverty | 2 | 2013 | 196 | 0.390 |
Why?
|
| Analgesics, Opioid | 3 | 2018 | 513 | 0.390 |
Why?
|
| Schizophrenic Psychology | 4 | 2015 | 141 | 0.390 |
Why?
|
| Health Priorities | 1 | 2012 | 28 | 0.370 |
Why?
|
| Research Design | 2 | 2015 | 630 | 0.360 |
Why?
|
| Logistic Models | 8 | 2025 | 1267 | 0.360 |
Why?
|
| Hospitals, Veterans | 2 | 2011 | 23 | 0.350 |
Why?
|
| Computers, Handheld | 1 | 2011 | 33 | 0.350 |
Why?
|
| Cell Phone | 1 | 2011 | 38 | 0.350 |
Why?
|
| Treatment Outcome | 13 | 2024 | 9167 | 0.350 |
Why?
|
| Severity of Illness Index | 8 | 2022 | 1981 | 0.340 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2018 | 224 | 0.340 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 135 | 0.340 |
Why?
|
| Aftercare | 1 | 2012 | 90 | 0.330 |
Why?
|
| Perioperative Care | 1 | 2013 | 188 | 0.330 |
Why?
|
| Biomedical Research | 1 | 2015 | 441 | 0.330 |
Why?
|
| Social Support | 3 | 2018 | 239 | 0.330 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 151 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2024 | 933 | 0.330 |
Why?
|
| Health Services Accessibility | 3 | 2019 | 491 | 0.320 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 197 | 0.320 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 219 | 0.320 |
Why?
|
| Drug Utilization | 2 | 2009 | 69 | 0.320 |
Why?
|
| Aged | 19 | 2025 | 20848 | 0.320 |
Why?
|
| Outpatients | 2 | 2009 | 105 | 0.310 |
Why?
|
| Tobacco Use Disorder | 2 | 2025 | 122 | 0.310 |
Why?
|
| Information Seeking Behavior | 1 | 2009 | 18 | 0.300 |
Why?
|
| Primary Health Care | 3 | 2015 | 391 | 0.300 |
Why?
|
| Alcohol Drinking | 3 | 2018 | 286 | 0.300 |
Why?
|
| Consumer Health Information | 1 | 2009 | 18 | 0.300 |
Why?
|
| Patient Dropouts | 1 | 2009 | 31 | 0.300 |
Why?
|
| Intensive Care Units | 1 | 2013 | 460 | 0.290 |
Why?
|
| Biomedical Technology | 1 | 2009 | 26 | 0.290 |
Why?
|
| Patient Education as Topic | 5 | 2018 | 378 | 0.270 |
Why?
|
| Patient Isolation | 3 | 2013 | 14 | 0.270 |
Why?
|
| Psychotherapy, Group | 1 | 2007 | 37 | 0.270 |
Why?
|
| Health Services | 1 | 2007 | 58 | 0.260 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2007 | 66 | 0.260 |
Why?
|
| Maryland | 4 | 2018 | 45 | 0.260 |
Why?
|
| Vaccination | 2 | 2022 | 311 | 0.240 |
Why?
|
| Internship and Residency | 1 | 2015 | 1134 | 0.240 |
Why?
|
| Community Mental Health Centers | 3 | 2015 | 6 | 0.240 |
Why?
|
| Anxiety Disorders | 3 | 2018 | 156 | 0.230 |
Why?
|
| Cotinine | 1 | 2025 | 15 | 0.230 |
Why?
|
| Marketing | 1 | 2025 | 24 | 0.230 |
Why?
|
| Surveys and Questionnaires | 7 | 2025 | 2859 | 0.220 |
Why?
|
| Kenya | 1 | 2024 | 9 | 0.220 |
Why?
|
| Baltimore | 3 | 2018 | 43 | 0.220 |
Why?
|
| Bupropion | 1 | 2024 | 22 | 0.220 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2013 | 504 | 0.210 |
Why?
|
| Tobacco Products | 1 | 2025 | 80 | 0.210 |
Why?
|
| Ambulatory Care | 2 | 2013 | 198 | 0.210 |
Why?
|
| Rural Population | 1 | 2025 | 171 | 0.210 |
Why?
|
| Cardiovascular Diseases | 2 | 2008 | 777 | 0.210 |
Why?
|
| Students | 1 | 2025 | 179 | 0.200 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 640 | 0.190 |
Why?
|
| Electroconvulsive Therapy | 1 | 2023 | 26 | 0.190 |
Why?
|
| Trust | 1 | 2023 | 101 | 0.190 |
Why?
|
| Cross Infection | 3 | 2013 | 159 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2007 | 647 | 0.180 |
Why?
|
| Physician's Role | 1 | 2003 | 186 | 0.180 |
Why?
|
| Postoperative Complications | 1 | 2013 | 2592 | 0.180 |
Why?
|
| Medicaid | 1 | 2024 | 260 | 0.170 |
Why?
|
| Crisis Intervention | 1 | 2021 | 13 | 0.170 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 306 | 0.170 |
Why?
|
| Quality of Life | 3 | 2022 | 1816 | 0.170 |
Why?
|
| Hepacivirus | 1 | 2022 | 137 | 0.170 |
Why?
|
| Chronic Disease | 1 | 2004 | 983 | 0.170 |
Why?
|
| Medicare | 1 | 2004 | 458 | 0.160 |
Why?
|
| Adolescent | 9 | 2025 | 9873 | 0.160 |
Why?
|
| Technology | 1 | 2020 | 35 | 0.160 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 57 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 1230 | 0.160 |
Why?
|
| Infection Control | 2 | 2011 | 132 | 0.160 |
Why?
|
| Fatigue | 1 | 2020 | 185 | 0.150 |
Why?
|
| Emergency Service, Hospital | 1 | 2004 | 593 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 35 | 0.150 |
Why?
|
| Rural Health Services | 1 | 2018 | 17 | 0.140 |
Why?
|
| Biomarkers | 1 | 2025 | 1931 | 0.140 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 53 | 0.140 |
Why?
|
| Avoidance Learning | 1 | 2018 | 21 | 0.140 |
Why?
|
| Anxiety | 3 | 2022 | 339 | 0.140 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 41 | 0.140 |
Why?
|
| Social Stigma | 1 | 2018 | 86 | 0.140 |
Why?
|
| Risk | 2 | 2013 | 665 | 0.140 |
Why?
|
| Risk Factors | 5 | 2014 | 5961 | 0.130 |
Why?
|
| PubMed | 1 | 2017 | 16 | 0.130 |
Why?
|
| Mental Health | 2 | 2018 | 202 | 0.130 |
Why?
|
| Motivation | 1 | 2020 | 310 | 0.130 |
Why?
|
| Utilization Review | 2 | 2009 | 25 | 0.130 |
Why?
|
| Arousal | 1 | 2018 | 173 | 0.130 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 156 | 0.130 |
Why?
|
| Text Messaging | 1 | 2017 | 35 | 0.120 |
Why?
|
| Qualitative Research | 1 | 2018 | 361 | 0.120 |
Why?
|
| Educational Status | 2 | 2015 | 202 | 0.120 |
Why?
|
| Young Adult | 6 | 2016 | 7026 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 517 | 0.120 |
Why?
|
| Pandemics | 1 | 2022 | 880 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2019 | 504 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2017 | 212 | 0.120 |
Why?
|
| Health Surveys | 3 | 2009 | 245 | 0.120 |
Why?
|
| Sex Factors | 3 | 2015 | 1127 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2016 | 175 | 0.120 |
Why?
|
| Problem-Based Learning | 1 | 2015 | 40 | 0.110 |
Why?
|
| Frontal Lobe | 1 | 1996 | 131 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 3904 | 0.110 |
Why?
|
| Gloves, Protective | 2 | 2011 | 3 | 0.110 |
Why?
|
| Early Medical Intervention | 1 | 2014 | 19 | 0.100 |
Why?
|
| Hospitals, Psychiatric | 1 | 2013 | 26 | 0.100 |
Why?
|
| Restraint, Physical | 1 | 2013 | 32 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2018 | 10273 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 1996 | 548 | 0.100 |
Why?
|
| Survivors | 1 | 2015 | 204 | 0.100 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2013 | 22 | 0.100 |
Why?
|
| Placebos | 1 | 2013 | 213 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2009 | 7215 | 0.090 |
Why?
|
| Interviews as Topic | 2 | 2014 | 376 | 0.090 |
Why?
|
| Hospital Departments | 1 | 2012 | 14 | 0.090 |
Why?
|
| General Practice | 1 | 2012 | 9 | 0.090 |
Why?
|
| Interview, Psychological | 1 | 2012 | 69 | 0.090 |
Why?
|
| Protective Clothing | 1 | 2011 | 4 | 0.090 |
Why?
|
| Surgery Department, Hospital | 1 | 2012 | 43 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2012 | 199 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2009 | 362 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 436 | 0.090 |
Why?
|
| Comprehension | 1 | 2012 | 84 | 0.090 |
Why?
|
| Risk Reduction Behavior | 2 | 2008 | 99 | 0.090 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 119 | 0.080 |
Why?
|
| Blood-Borne Pathogens | 1 | 2010 | 4 | 0.080 |
Why?
|
| Personality Inventory | 1 | 2011 | 112 | 0.080 |
Why?
|
| Curriculum | 1 | 2015 | 615 | 0.080 |
Why?
|
| Evidence-Based Medicine | 2 | 2010 | 458 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 514 | 0.080 |
Why?
|
| Time Factors | 3 | 2013 | 5561 | 0.080 |
Why?
|
| Length of Stay | 1 | 2013 | 833 | 0.070 |
Why?
|
| Disease Notification | 1 | 2008 | 4 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 569 | 0.070 |
Why?
|
| Preventive Health Services | 1 | 2008 | 39 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 468 | 0.070 |
Why?
|
| Truth Disclosure | 1 | 2008 | 92 | 0.070 |
Why?
|
| Incidence | 1 | 2012 | 1714 | 0.070 |
Why?
|
| Office Visits | 1 | 2007 | 52 | 0.060 |
Why?
|
| Demography | 1 | 2007 | 189 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2008 | 245 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2013 | 4664 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2004 | 771 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 488 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2007 | 295 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 2 | 2008 | 231 | 0.060 |
Why?
|
| Bronchitis, Chronic | 1 | 2004 | 3 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2005 | 82 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2024 | 1739 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 76 | 0.060 |
Why?
|
| Idaho | 1 | 2024 | 9 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2011 | 713 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2018 | 323 | 0.050 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2024 | 7 | 0.050 |
Why?
|
| Pulmonary Emphysema | 1 | 2004 | 43 | 0.050 |
Why?
|
| Affective Symptoms | 1 | 2024 | 56 | 0.050 |
Why?
|
| China | 2 | 2015 | 264 | 0.050 |
Why?
|
| Registries | 1 | 2009 | 985 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2004 | 175 | 0.050 |
Why?
|
| Probability | 1 | 2003 | 364 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2008 | 635 | 0.050 |
Why?
|
| Theta Rhythm | 1 | 2023 | 38 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2011 | 3106 | 0.050 |
Why?
|
| Family Practice | 1 | 2002 | 85 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2023 | 134 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 1008 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2005 | 1791 | 0.040 |
Why?
|
| Endocrinology | 1 | 2002 | 50 | 0.040 |
Why?
|
| Decision Making | 1 | 2007 | 694 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2004 | 1540 | 0.040 |
Why?
|
| Sofosbuvir | 1 | 2019 | 9 | 0.040 |
Why?
|
| Public Health | 1 | 2018 | 155 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 386 | 0.030 |
Why?
|
| Marital Status | 1 | 2015 | 45 | 0.030 |
Why?
|
| Hallucinations | 1 | 2015 | 31 | 0.030 |
Why?
|
| Thinking | 1 | 1996 | 39 | 0.030 |
Why?
|
| Afghan Campaign 2001- | 1 | 2014 | 5 | 0.030 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 344 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 61 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2014 | 101 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2013 | 35 | 0.030 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2013 | 17 | 0.020 |
Why?
|
| Child | 1 | 2024 | 7618 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1996 | 505 | 0.020 |
Why?
|
| Cost Savings | 1 | 2013 | 71 | 0.020 |
Why?
|
| Surgical Attire | 1 | 2011 | 1 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 52 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1957 | 0.020 |
Why?
|
| Patient Admission | 1 | 2011 | 122 | 0.020 |
Why?
|
| HIV Seropositivity | 1 | 2010 | 53 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2011 | 183 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 500 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2009 | 94 | 0.020 |
Why?
|
| Emotions | 1 | 2013 | 377 | 0.020 |
Why?
|
| Neoplasms | 1 | 2004 | 3242 | 0.020 |
Why?
|
| Peer Review, Health Care | 1 | 2008 | 7 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2009 | 311 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2010 | 503 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2008 | 163 | 0.020 |
Why?
|
| Data Collection | 1 | 2008 | 381 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1096 | 0.020 |
Why?
|
| Recurrence | 1 | 2009 | 1211 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 2480 | 0.020 |
Why?
|
| Hepatitis B Vaccines | 1 | 2005 | 18 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1965 | 0.010 |
Why?
|
| Immunization | 1 | 2005 | 165 | 0.010 |
Why?
|
| Diagnosis-Related Groups | 1 | 2002 | 22 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 1805 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2002 | 312 | 0.010 |
Why?
|